Home Newsfeeds Morgan Stanley Maintains Underweight on Southern, Raises Price Target to $63

Morgan Stanley Maintains Underweight on Southern, Raises Price Target to $63

Morgan Stanley analyst Stephen Byrd maintains Southern (NYSE:SO) with a Underweight and raises the price target from $58 to $63.

byBenzinga Newsdesk

July 21, 2022

1 minute read

Morgan Stanley analyst Stephen Byrd maintains Southern (NYSE:SO) with a Underweight and raises the price target from $58 to $63.

Pentair’s Structural Margin Enhancements Undervalued, Analyst Sees Positive Momentum In Pool Business

By Shivani Kumaresan

December 13, 2:10 PM

KeyBanc analyst Jeffrey Hammond upgraded the shares of Pentair Plc (NYSE: PNR) from Sector Weight to Overweight

PNR

Reported Late Monday, Molecular Partners Presents New Preclinical Data Supporting Its MP0533 DARPin T-Cell Engager For The Treatment Of AML

By Benzinga Newsdesk

December 13, 1:30 AM

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal

MOLN

Perspective Therapeutics Announces First Patient Dosed In Phase 1/2a Study of [(212)Pb]VMT-α-NET For Treatment Of Advanced SSTR2-Positive Neuroendocrine Tumors

By Benzinga Newsdesk

November 8, 9:01 AM

Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), announced today that the first patient was dosed at Washington University in St Louis in the Company's Phase 1/2a trial evaluating the

CATX

Pervasip Converts $15M Debt, Moves Toward Profitability With Cannabis Spin-Off

By Jelena Martinovic

February 2, 2:38 PM

A key aspect of the restructuring is converting over 80% of Pervasip debt into equity in the new cannabis-focused entity.

PVSP

Morgan Stanley Maintains Underweight on Southern, Raises Price Target to $63

Related Posts

Pentair’s Structural Margin Enhancements Undervalued, Analyst Sees Positive Momentum In Pool Business

Reported Late Monday, Molecular Partners Presents New Preclinical Data Supporting Its MP0533 DARPin T-Cell Engager For The Treatment Of AML

Perspective Therapeutics Announces First Patient Dosed In Phase 1/2a Study of [(212)Pb]VMT-α-NET For Treatment Of Advanced SSTR2-Positive Neuroendocrine Tumors

Pervasip Converts $15M Debt, Moves Toward Profitability With Cannabis Spin-Off